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Abstract 
Background & Aims: Disturbances in the control of ion transport lead to epithelial barrier 
dysfunction in patients with colitis. Enteric glia regulate intestinal barrier function and colonic 
ion transport. However, it is not clear whether enteric glia are involved in the epithelial hypo-
responsiveness. We investigated enteric glial regulation of ion transport in mice with 
trinitrobenzene sulphonic acid- or dextran sodium sulfate-induced colitis and in Il10-/- mice.  
Methods: Electrically-evoked ion transport was measured in full-thickness segments of colon 
from CD1 and Il10-/- mice with or without colitis in Ussing chambers. Nitric oxide (NO) 
production was assessed using amperometry. Bacterial translocation was investigated in the 
liver, spleen and blood of mice.  Results: Electrical stimulation of the colon evoked a 
tetrodotoxin-sensitive chloride secretion. In mice with colitis, ion transport almost completely 
disappeared. Inhibiting inducible NO synthase (NOS2), but not neuronal NOS (NOS1), partially 
restored the evoked secretory response. Blocking glial function with fluoroacetate, which is not 
a NOS2 inhibitor, also partially restored ion transport. Combined NOS2 inhibition and 
fluoroacetate administration fully restored secretion.  Epithelial responsiveness to vasoactive 
intestinal peptide was increased after enteric glial function was blocked in mice with colitis.  In 
colons of mice without colitis, NO was produced in the myenteric plexus almost completely via 
NOS1. NO production was increased in mice with colitis, compared to mice without colitis; a 
substantial proportion of NOS2 was blocked by fluoroacetate administration. Inhibition of 
enteric glial function in vivo reduced the severity of trinitrobenzene sulphonic acid -induced 
colitis and associated bacterial translocation.  
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Conclusions: Increased production of NOS2 in enteric glia contributes to the dysregulation of 
intestinal ion transport in mice with colitis.  Blocking enteric glial function in these mice restores 
epithelial barrier function and reduces bacterial translocation.  
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Introduction  
Inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis, are characterized by 
diarrhea, weight loss, malabsorption of water and nutrients, resulting in debilitating illness1, 2. 
The dysregulation of water and ion transport occurs as a result of altered epithelial function 
and is directly involved in the symptoms of IBD.  However, the mechanisms underlying this 
dysfunction are largely unresolved and treatment options are limited3. 
Increased NO production has been implicated in intestinal inflammation, although the function 
of NO has been debated as both pro- and anti-inflammatory4, 5. The increase in NO occurs 
through upregulation of NOS2 in epithelial and immune cells, and in neurons and enteric glial 
cells of the enteric nervous system (ENS)6-11. Enteric glia, long considered to be primarily 
supportive cells of the ENS, are now known to be actively involved in the maintenance of 
epithelial barrier function12. NOS2-derived NO has been shown to induce epithelial 
hyporesponsiveness to secretagogues that normally induce apically directed chloride 
secretion13, 14. We have recently described a role for enteric glia in the modulation of nicotinic 
cholinergic receptor-mediated ion transport15. However, whether enteric glia are involved in 
dysregulating intestinal ion transport during intestinal inflammation is not known.  
During intestinal inflammation, enteric glia undergo reactive gliosis16, 17, respond to and 
produce inflammatory mediators16, 18, 19 and are involved in the breakdown of epithelial barrier 
function20, 21.  It has been speculated that enteric glia are involved in the regulation of ion 
transport during experimental colitis, based on the localization and upregulation of NOS2 in 
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enteric glia during intestinal inflammation8.  However, a functional role for NOS2 in enteric glia 
remains to be established. 
We tested the hypothesis that enteric glia of the ENS are involved in the dysregulation of ion 
transport in colitis by directly targeting them using the glial metabolic inhibitor fluoroacetate. 
Fluoroacetate has been well characterized as a method of reversibly inhibiting glia metabolic 
function in the central nervous system, where it is preferentially taken up by astrocytes and 
their function is reversibly inhibited22-24. Enteric glia have many similarities to astrocytes25, 26, 
and within the ENS, the fluoroacetate metabolite fluorocitrate has been successfully used to 
demonstrate their role in the regulation of motility27.  Here we utilize fluoroacetate in 
conjunction with measurement of intestinal ion transport and NO release from the myenteric 
plexus to examine the role of enteric glia in the dysregulation of ion transport in the inflamed 
colon in three mouse models of colitis. We also assessed human colonic biopsies to establish if 
in the absence of the enteric plexuses we would observe epithelial hyporesponsiveness and if 
so, if that was reversed by treatment with fluoroacetate. 
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Methods 
Animals. Wild-type male CD1 mice (6-8 weeks; Charles River, Montreal, QC) were used unless 
otherwise stated. A genetic model of colitis using Il10-/- mice generated on a 129Sv/Ev 
background was also used, and compared with Sv/Ev wildtype controls. Il10-/- mice develop 
intestinal inflammation as they age, and therefore mice 16-20 weeks of age were used.  Animal 
protocols were approved by the University of Calgary Animal Care Committee, and were carried 
out in accordance with the guidelines of the Canadian Council on Animal Care. Animals were 
housed in polystyrene cages with free access to food and tap water and maintained on a 12h 
light-dark cycle in a temperature and humidity controlled room. All animals were killed by 
cervical dislocation under deep isofluorane anesthesia. 
 
Colitis. Colitis was induced using TNBS (0.1mL of 30mg/mL TNBS in 30% ethanol) administered 
3 cm intrarectally in animals lightly anesthetized with isofluorane, and DSS (5% w/v) dissolved 
in drinking water for 5 days followed by 2 days of normal drinking water. TNBS-treated animals 
were sacrificed 3 days post-treatment and DSS-treated animals were sacrificed 7 days after 
treatment. The extent of damage induced by intestinal inflammation was assessed in each 
model using a modified version of an established macroscopic damage score28, 29. Briefly, the 
colonic damage score consisted of the length of damage or length of ulceration (cm), summed 
with scores for the presence or absence of erythema (0 or 1), diarrhea (0 or 1; defined as loose 
or watery stool), fecal blood (0 or 1), and adhesions (0, 1 for mild, or 2 for severe). Length of 
colon (cm) was also recorded. 
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Chronic TNBS colitis. TNBS colitis was induced in mice as described above and animals were 
subsequently allowed to recover for 3 weeks. Animals had similar initial weight loss as the acute 
TNBS-treated mice (Table 1).  
 
Measurement of Electrogenic Ion Transport. Full-thickness distal colonic segments were 
mounted in Ussing chambers (0.5 cm2 opening) and held under voltage-clamp conditions in 
oxygenated (95% O2, 5% CO2) Krebs buffer (pH 7.4) that contained (in mM): NaCl (117), KCl 
(4.8), CaCl2 (2.5), MgCl2 (1.2), NaHCO3 (25), NaH2PO4 (1.2) and D-glucose (11). Electrogenic 
movement of ions across the epithelium was recorded as short-circuit current (ISC, µA/cm2), 
where the change in ISC (ΔISC) is the peak post-stimulus value subtracted from the stable pre-
stimulus baseline. Drugs were added serosally unless otherwise specified and remained in the 
bath for the duration of the experiment. Electrical field stimulation (EFS; 50V, 10Hz, 3s) was 
applied in the presence or absence of the following inhibitors: the NOS1 inhibitor S-Methyl-L-
thiocitrulline (SMTC; 10µM, Calbiochem, La Jolla, CA), the NOS2 inhibitor N-(3-Aminomethyl) 
benzylacetamidine (1400W; 10µM, Calbiochem), and the neurotoxin tetrodotoxin (TTX; 500nM, 
Tocris Bioscience, Ellisville, MO). Additionally, the following agonists were used: substance P 
(100μM, Sigma-Aldrich, Oakville, ON), and vasoactive intestinal peptide (VIP; 100nM, 
Calbiochem), the specificity of which was assessed with the VIP antagonist [D-p-Cl-Phe6, Leu17]-
VIP (300nM, Tocris). At the conclusion of each experiment the adenylate cyclase activator 
forskolin (10µM, Sigma) was added to the chamber. The involvement of chloride ions was 
assessed using chloride-free Krebs buffer (pH 7.4) that contained (in mM): D-gluconic acid, 
sodium salt (117), D-gluconic acid, potassium salt (4.8), NaHCO3 (25), NaH2PO4 (1.2), D-gluconic 
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acid, hemimagnesium salt (1.2), D-gluconic acid, calcium salt (2.5), and D-glucose (11).  
 
Electrochemical Detection of Nitric Oxide. Continuous amperometric monitoring of NO release 
was conducted on the mucosal surface of full-thickness colon and on myenteric ganglia in 
myenteric plexus-longitudinal muscle preparations as previously described15, 30. Briefly, an NO 
oxidation current was recorded using a 40µm diameter boron-doped diamond (BDD) 
microelectrode (described elsewhere15, 30, 31). A stainless steel wire served as the counter 
electrode and a “no leak” Ag|AgCl electrode (EE009, ESA Biosciences Inc., Sunnyvale, CA) was 
used as the reference electrode.  Amperometric measurements were carried out using a 
BioStat™ multi-mode potentiostat (ESA Biosciences). The BDD microelectrode was reproducibly 
positioned over ganglia using a micromanipulator (Model 25033, Fine Scientific Tools, North 
Vancouver, BC).  The electrode was held at a detection potential of +1.0 V vs. Ag|AgCl, which 
was sufficient to oxidize NO at a mass-transfer limited rate. As previously described15, 30, tissues 
were continually perfused with Krebs’ buffer at a flow rate of 2 mL/min. For experiments 
investigating NO release from the mucosa, deoxycholic acid (DCA; Sigma; 1mM) was applied for 
30 min and NO release measured at 0 and 30min. The BDD microelectrode was placed 200µm 
above the mucosal tissue surface for 40s and the currents were recorded at +0.85 V and +1.0 V 
vs. Ag|AgCl. The difference in the current obtained was due to the oxidation of NO and 
removed interferences from mucosal melatonin and serotonin release. DCA has previously 
been demonstrated to cause NO release from NOS2 the intestinal epithelium32, 33. For 
experiments investigating NO release from the myenteric plexus, a local superfusion pipette 
placed within 100µm of the tissue for 20s containing veratridine (10µM; Sigma) was used to 
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depolarize enteric neurons in the presence or absence of the inhibitors SMTC (10 µM) and 
1400W (10µM).  
 
Bacterial Translocation 
Examination of bacterial translocation was performed in mice with TNBS colitis or controls, with 
animals receiving saline or fluoroacetate injections (1mg/kg, IP) every 12h for 3 days. Mice were 
euthanized by cervical dislocation under deep isofluorane anesthesia and their blood, liver, and 
spleen tested for translocated bacteria as previously described13, 34. Briefly, blood was collected 
by cardiac puncture and liver and spleen removed using sterile techniques.  Fecal samples acted 
as a positive control.  Each tissue and fecal sample was standardized by weight.  The samples 
were homogenized in 2mL of sterile phosphate buffered saline and serial dilutions of aliquots 
(0.1ml) were plated onto Columbia blood agar to enumerate total aerobic and facultative 
bacteria and plated onto MacConkey’s agar to enumerate aerobic and facultative gram-
negative enteric bacilli. The plates were incubated at 37°C in aerobic conditions and the 
number of colony forming units (CFU) measured at 24h and 48h. 
 
Fluoroacetate Treatment. The glial metabolic inhibitor fluoroacetate (5mM, Sigma) was applied 
for 120min in Ussing chamber experiments prior to EFS or the addition of agonists and 60min 
for dissected longitudinal muscle-myenteric plexus preparations in electrochemical detection 
studies.  
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Minimum Inhibitory Concentration Test. Bacterial growth in the presence and absence of 
fluoroacetate was assessed using the minimum inhibitory concentration test, as previously 
described35. Escherichia coli 91801 and Enterobacter cloacae 10404 bacteria were cultured in LB 
media for 24 hours. 100 µl of bacteria at a final concentration of 1x106 CFU/mL was then added 
into individual wells of a 96 well plate. Each well also received 100µl of FA at concentrations 
ranging from 0.078-200µM. Plates were sealed and incubated for 48 h and subsequently the 
O.D.600 for each well was measured, giving an estimate of bacterial concentration in the sample.  
 
Human Biopsies.  Human colonic biopsy samples were acquired from the distal and 
rectosigmoid colon during colonoscopy or sigmoidoscopy procedures after informed consent 
from patients with irritable bowel syndrome (n=2), Crohn’s disease (n=5) or ulcerative colitis 
(n=4). Samples were obtained from endoscopically inflamed (but not ulcerated) or 
uninflamed/normal regions. Adjacent biopsies were assessed by pathologists to verify the 
presence or absence of inflammation. Biopsies were immediately placed in cold Krebs/Glucose 
buffer (Krebs + 10mM glucose) and transported to the lab on ice. Samples were treated with 
Krebs buffer with or without FA (5mM) in an oxygenated chamber (5% CO2 + 95% O2) for 120 
min at room temperature. Samples were then mounted into Ussing chambers (Physiologic 
Instruments, San Diego, CA; biopsy specific P2308 sliders) and stimulated with EFS (50V, 10Hz, 
5s).  These studies were approved by the University of Calgary Conjoint Human Research Ethics 
Board.   
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Statistics.  Data are presented as mean ± standard error of the mean (SEM) and were compared 
using one-way ANOVA followed by post-hoc pair-wise comparisons with Tukey’s test, unless 
otherwise stated. P <.05 was accepted as a level of statistically significant difference. 
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Results 
The role of NO and enteric glia in the regulation of baseline electrogenic intestinal ion 
transport  
EFS induced a monophasic increase in ISC (42±13 μA/cm2; n=6; Figure 1A and 1B). This response 
was abolished in the presence of TTX (0.5±2 μA/cm2; n=4; P<.01 vs. vehicle), indicating that it is 
neurally mediated.  The ISC response was due to epithelial chloride secretion, as the ΔISC was 
abolished in chloride free buffer (0.5±0.5 μA/cm2; n=4; P<.001 vs. vehicle).  Electrogenic ion 
transport was unaffected by SMTC, 1400W, or both inhibitors in combination (Figure 1B) in 
untreated animals or in mice treated with saline enemas.  
 
In order to assess the role of enteric glia we used the metabolic inhibitor fluoroacetate22-24. 
Under control conditions, fluoroacetate treatment did not alter the ΔISC in response to EFS in 
untreated animals (41±8 μA/cm2; n=11; P>.05) or animals treated with a saline-enema (36±6; 
n=6; P>.05).  These data suggest that neither enteric glia nor NO play a regulatory role in 
electrogenic ion transport under physiological conditions.      
 
Ion transport is inhibited during colitis and is restored by inhibiting NOS2 
DSS and TNBS treatment induced weight loss (P<.001 vs. respective controls), extensive 
inflammation and shortening of the colon (Table 1).  Similarly, Il10-/- mice had extensive 
intestinal inflammation with damage scores that were comparable to the chemical models of 
colitis (Table 1).  
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Following the induction of colitis with either TNBS or DSS, the secretory response to EFS was 
virtually abolished (Figures 1C and 1D). SMTC had no effect on this response, while 1400W 
partially restored it, and a combination of SMTC and 1400W were not significantly different to 
1400W alone (Figure 1C).  These data show that in colitis, NO derived from NOS2 is an 
important inhibitor of electrogenic ion transport.   
 
Inhibiting enteric glial metabolism restores ion transport in colitis 
In both TNBS and DSS colitis, fluoroacetate treatment significantly restored the secretory 
response to EFS and a combination of fluoroacetate and 1400W fully restored the secretory 
response (Figures 2A and 2B).  TTX completely inhibited the restored response following 1400W 
treatment in TNBS colitis (2±1μA/cm2; n=4; P<.01 vs. 1400W) and DSS colitis (2±2μA/cm2; n=4; 
P<.001 vs. 1400W), and after fluoroacetate treatment in TNBS colitis (2±1 μA/cm2; n=3; P<.001 
vs. TNBS fluoroacetate) and DSS colitis (1±1 μA/cm2; n=3; P<.05 vs. DSS fluoroacetate). The EFS 
response following fluoroacetate treatment was absent in chloride free buffer for both models 
of colitis (TNBS: 2±1 μA/cm2, n=4; P<.01 vs. saline control; DSS: 1±1 μA/cm2, n=4, P<.01 vs. 
control).  These data show that in colitis, enteric glia are involved in the inhibition of 
electrogenic neurally-mediated chloride secretion.  In Il10-/- mice, the ΔISC following EFS was 
greatly reduced compared to SvEv wildtype controls. Fluoroacetate treatment had no effect on 
the ΔISC in SvEv mice, but partially restored the secretory response in Il10-/- mice (Figure 2C). 
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Enteric glial dysregulation is reversed following recovery from colitis 
Animals that were allowed to recover for 3 weeks following the induction of TNBS colitis had 
similar responses to EFS compared to controls in the presence and absence of fluoroacetate 
(Figure 3A; P>.05).  The secretory response to forskolin in TNBS-treated mice was also 
comparable to controls in the presence and absence of fluoroacetate (Figure 3B; P>0.5).  
 
Restoration of the secretory response to neural stimulation in colitis is partially mediated by 
VIP 
In order to identify a neuronal mediator of the ion transport response after fluoroacetate 
treatment, we first determined that the effect of fluoroacetate was not due to a change in 
epithelial responsiveness to the cyclic AMP (cAMP)-dependent secretagogue, forskolin, which 
acts directly on the epithelium.  Forskolin elicited a large secretory response in the distal colon 
under control conditions, following saline enema treatment (Figures 4A and 4B), and in SvEv 
mice (111±11 μA/cm2; n=3).  The response to forskolin was unaffected by fluoroacetate in 
control and saline treated conditions.  The magnitude of the forskolin-induced ΔISC was 
significantly lower compared to the respective controls in TNBS (Figure 4A), DSS (Figure 4B), 
and Il10-/- mice (40±7 μA/cm2; n=3; P<.001). The response to forskolin was unchanged by 
fluoroacetate (Figures 4A and 4B) or 1400W or a combination of both (not shown) following 
TNBS or DSS treatment.  These data suggested that the fluoroacetate treatment did not alter 
the epithelial responsiveness to forskolin. 
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We next examined substance P and VIP as they are well-known mediators of epithelial chloride 
secretion36-38.  Substance P (100μM) elicited a modest increase in ΔISC (control: 13±4 μA/cm2, 
n=7; saline control: 7±3 μA/cm2, n=4) that was reduced during intestinal inflammation (TNBS: 
4±1 μA/cm2, n=3; DSS: 1±1 μA/cm2, n=4; P<.05 vs. respective controls). Fluoroacetate 
treatment did not restore the secretory response to substance P (TNBS fluoroacetate: 1±1 
μA/cm2, n=3; DSS fluoroacetate: 1±1 μA/cm2, n=4; P>.05 vs. respective inflamed condition). 
 
VIP (100 nM) elicited a robust increase in ΔISC under control and saline control conditions that 
was unchanged by fluoroacetate treatment (Figures 4C and 4D). The selective VIP receptor 
antagonist [D-p-Cl-Phe6, Leu17]-VIP (300nM) completely blocked the response to VIP under 
control (0±2 μA/cm2, n=3) and saline control (1±1 μA/cm2, n=3) conditions with or without 
fluoroacetate treatment (control fluoroacetate: -2±1 μA/cm2, n=3; saline control fluoroacetate: 
0±0 μA/cm2, n=3; P>.05 vs. respective control). The response to VIP was decreased in TNBS 
(Figure 4C, P<.001 vs. saline control) and DSS colitis (Figure 4D, P<.001 vs. control).  
Fluoroacetate treatment partially restored the VIP response in both TNBS (Figure 4C) and DSS 
(Figure 4D) treated mice.  These restored responses were blocked by [D-p-Cl-Phe6, Leu17]-VIP 
(TNBS fluoroacetate: 2±1 μA/cm2, n=3; DSS fluoroacetate: 1±1 μA/cm2, n=3; P>.05 vs. 
respective control). 
 
TTX did not alter the ΔISC response to VIP in saline enema control (Figure 4E) and untreated 
control conditions (Figure 4F). This response was also unaffected by fluoroacetate. In colitis, 
TTX did not alter the reduced ΔISC in response to VIP (data not shown).  However, following 
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fluoroacetate treatment, TTX now blocked the VIP-induced ΔISC in both TNBS colitis (Figure 4E) 
and DSS colitis (Figure 4F).   These data suggest that VIP is a mediator of the neurally evoked ion 
transport response that occurs after fluoroacetate treatment in colitis.   
 
Nitric oxide is released from the myenteric plexus following neuronal activation  
Having determined that NO from NOS2 and enteric glia is the inhibitory mediator of secretion, 
we wished to determine whether NO release occurs in the myenteric plexus.  Whilst the 
traditional view of enteric neural regulation of secretion considers that the submucosal plexus 
is responsible for secretion and the myenteric plexus for motility, our work and that of others 
suggests that both plexuses together coordinate ion transport8, 15, 39-41. Given the extreme 
technical difficulty in dissecting the isolated submucosal plexus, we investigated NO signaling 
within the myenteric plexus. We measured NO release following the application of veratridine, 
which excites enteric neurons42. Under physiological conditions, veratridine caused an increase 
in NO release that was insensitive to fluoroacetate (Figure 5A). This response was largely 
derived from NOS1 as it was almost completely blocked by treatment with SMTC (Figure 5B).  
There was a small NOS2 component that was sensitive to 1400W. SMTC and 1400W together 
completely blocked the NO release (Figure 5B).  In TNBS and DSS colitis, veratridine caused an 
increase in NO release that was larger than that observed in controls and was only partially 
blocked by SMTC, significantly reduced by 1400W, and was completely inhibited by SMTC and 
1400W together (Figures 5C and 5D).   
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Inhibiting enteric glial metabolism blocks NO release from the myenteric plexus during 
intestinal inflammation 
We next assessed if inhibiting glial metabolism would decrease the release of NO in colitis.  In 
both TNBS- and DSS-induced colitis, tissues treated with fluoroacetate had reduced NO release 
from the myenteric plexus following veratridine stimulation compared to untreated TNBS tissue 
(P<.001).  This was completely inhibited by SMTC or in combination with 1400W (Figures 5E and 
5F), but unchanged by 1400W alone. These data suggest that fluoroacetate inhibits the ability 
of enteric glia to be stimulated by enteric nerves to produce NO from NOS2.   
 
Fluoroacetate is not a nitric oxide synthase 2 inhibitor 
We examined the ability of fluoroacetate to inhibit NO production using DCA, which stimulates 
NO production from NOS2 in the intestinal mucosa. In the absence of stimulation, the mucosa 
had a low basal production of NO. DCA treatment increased the production of NO, which was 
completely blocked by 1400W (Figure 6).  The effect of DCA remained unchanged by 
fluoroacetate treatment (Figure 6).  These data suggest that fluoroacetate is not a NOS2 
inhibitor and reaffirms its preferential inhibitory activity on glia. 
 
Bacterial translocation following intestinal inflammation was decreased by in vivo 
fluoroacetate treatment  
We assessed the effect of fluoroacetate treatment in vivo on damage score and bacterial 
translocation.  In animals without colitis, no damage score was recorded. The average damage 
score of TNBS treated animals was 10.1±1 (n=9) and fluoroacetate treatment reduced the 
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average damage score to 6.3±1 (n=7; P<.05 vs. TNBS), with the major difference in damage 
score being an absence of ulcerations in fluoroacetate-treated animals.  In animals without 
colitis, no bacterial translocation was detected (Table 2). However, in TNBS treated animals, 
hemolytic bacteria were found in 22% of blood samples, 56% of liver samples, and 78% of 
spleen samples. Gram negative bacteria were found in 11% of blood samples, 67% of liver 
samples, and 33% of spleen samples. In animals with TNBS colitis treated with fluoroacetate, 
hemolytic bacteria were found in 0% of blood samples, 14% of liver samples, and 14% of spleen 
samples (P<.05 vs. TNBS spleen; Fisher’s exact test). Gram negative bacteria were found in 0% 
of blood samples, 14% of liver samples, and 14% of spleen samples.   
 
Finally, we investigated whether fluoroacetate was acting as an antibacterial agent; instead of 
preventing bacterial translocation it could be killing bacteria present in the gut, blood, and 
organs. Over a range of concentrations, fluoroacetate (0.078-200 µM) did not alter the growth 
of Escherichia coli 91801 and Enterobacter cloacae 10404 bacteria in culture.  
 
Colonic biopsies from IBD patients have normal ion transport  
We found no difference in the ion transport response to EFS between biopsies from the 
inflamed (17.0 ± 4.5 μA/cm2; +FA 18.9 ± 4.7 μA/cm2; n=3) and uninflamed (19.0 ± 3.4 μA/cm2; 
+FA 14.8 ± 2.4 μA/cm2; n=11) regions of the colon in the presence or absence of fluoroacetate. 
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Discussion 
The aim of this study was to investigate the role of NO and enteric glia on the regulation of 
epithelial ion transport during intestinal inflammation. Using chemical and genetic mouse 
models of colitis and the glial-specific metabolic inhibitor fluoroacetate, we have demonstrated 
that enteric glia inhibit electrogenic epithelial ion transport through NO release from NOS2 
during colitis. This occurs independently of the neuronal NOS isoform NOS1.  The functional 
significance of these pathways was shown by inhibiting enteric glial function in vivo, 
substantially reducing inflammation and bacterial translocation in colitis.  
 
Our findings in colitis are in contrast to the normal physiological regulation of electrogenic 
epithelial ion transport in the colon. The increase in chloride secretion in control mice appears 
to be mediated solely by enteric nerves, since neither glial metabolic inhibition nor the 
inhibition of NO release have an effect. This finding is supported by previous work in the ENS 
using the fluoroacetate metabolite fluorocitrate, which did not inhibit ion transport in vivo 
under physiological conditions27. These results are interesting given our previous findings that 
nicotinic cholinergic signaling in myenteric ganglia mobilizes NO from NOS2 in enteric glia, 
which modulates epithelial ion transport under physiological conditions15.  In contrast to 
nicotinic cholinergic stimulation, EFS releases many excitatory and inhibitory neurotransmitters 
from neurons within the ENS, including acetylcholine, substance P and other tachykinins, VIP, 
adenosine triphosphate, serotonin, and NO43.  Given that nicotinic cholinergic activation 
represents only one component of this complex system, it is perhaps not surprising that there 
are differences when nicotinic stimulation is compared to EFS.  
 21 
During intestinal inflammation, the intestinal epithelium and neural secretomotor pathways are 
hyporesponsive to secretory stimuli, including the cAMP secretagogue IBMX, acetylcholine, and 
neural stimulation, persisting even after active inflammation has resolved8, 44-49. The 
mechanisms mediating epithelial ion transport hyporesponsiveness are not well understood3. 
The ENS has been implicated, since removal of the submucosal plexus reverses the 
hyporesponsiveness of the epithelium3. Nitric oxide has also been implicated; in a mouse model 
of colitis, inhibiting NOS2 activation partially restored physiological ion transport following a 
neural-specific stimulus48. The upregulation of NOS2 during intestinal inflammation has been 
well established7-9. We confirmed that neural stimulation during intestinal inflammation 
resulted in greater NO release, due to an increase in NOS2 activity in the myenteric plexus. 
Additionally, we further investigated the role of NO and confirmed the findings of 
MacNaughton et al.48 demonstrating that it was specifically NOS2 inhibition which restored ion 
transport, while NOS1 inhibition had no effect. Enteric glia are known to be a major source of 
NOS2 within the ENS, and a role for enteric glia in the regulation of epithelial ion transport 
during intestinal inflammation has been speculated8. Using fluoroacetate to directly investigate 
the role of enteric glia, we substantially reversed the inhibition of electrogenic ion transport 
following intestinal inflammation, suggesting that enteric glia play an important role in the 
inhibition of epithelial ion transport during colitis. Previous work in the ENS has observed that 
fluorocitrate appears solely to inhibit energy dependent processes in enteric glia27. In our study, 
fluoroacetate prevented NO release specifically from NOS2 without altering NOS1-mediated NO 
release or inhibiting NOS2 itself, suggesting that fluoroacetate directly targets enteric glial 
metabolism.  
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An interesting observation was the additive effect of the inhibition of NOS2 and metabolic 
inhibition of enteric glia in TNBS colitis. In contrast, the electrochemical data suggested that 
enteric glial NO release from the myenteric plexus is completely inhibited following either the 
inhibition of NOS2 or enteric glial metabolism. There is a difference between these 
preparations that helps explain these data.  Nitric oxide sensing was done on longitudinal 
muscle-myenteric plexus preparations, while the ion transport experiments were conducted in 
full-thickness tissue.  Therefore there may be incomplete inhibition in the full-thickness tissue 
due to penetrance issues. Alternatively, other cellular components or factors regulate the 
release of NO within the gut wall. The intestinal epithelium itself produces NO during intestinal 
inflammation10, 11. Additionally, infiltrating immune cells could produce NO and modulate the 
system, although this has not been explored. Finally, other glial populations are present in the 
gut such as mucosal glia, which help maintain the epithelial barrier and play a role in antigen 
presentation12, 16, 20.  However, we do not yet have an adequate way to isolate glial subtypes.  
 
To preclude model-specific effects of our observations, three different models of murine colitis 
were tested. The chemical models, TNBS and DSS, are acute models of colitis characterized by 
extensive epithelial damage, although with significant differences in the manifestation of this 
damage.  The Il10-/- model represents a chronic inflammatory model that develops postnatally 
and persists over time.  All three models have impaired electrogenic ion transport that is 
reversed by inhibiting glial metabolism. The commonality of enteric glial regulation of intestinal 
ion transport via NO across multiple models provides good evidence for a common mechanism 
that may be relevant in IBD. 
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Chloride secretion is regulated at the level of the epithelium primarily by cAMP, but impaired 
cAMP-mediated secretion during colitis was not altered by fluoroacetate. Similarly, substance P 
had an impaired secretory response during intestinal inflammation that was unaltered by 
fluoroacetate. These observations suggest that enteric glia do not directly mediate epithelial 
responsiveness to secretagogues. However, VIP, another modulator of ion transport, had an 
impaired secretory response during intestinal inflammation that was partially reversed by 
fluoroacetate, and was sensitive to TTX, suggesting that VIP may modulate electrogenic ion 
transport with actions on or through both neurons and enteric glia. VIP has been identified in 
the majority of neurons in the submucosal plexus of the middle and distal mouse colon50 and 
can act as a non-adrenergic non-cholinergic inhibitory neurotransmitter within the ENS, similar 
to NO38, 51. Indeed, VIP colocalizes with NOS1 in the myenteric plexus37, 52, 53. Nitric oxide can 
stimulate VIP release as demonstrated through the application of NO donors, and NOS 
inhibitors can block VIP release54, 55. VIP release could be altered by NOS2 inhibition or the 
metabolic inhibition of enteric glia during colitis, and therefore when enteric glia are 
metabolically inhibited, enteric neurons are uninhibited, leading to the restoration of the 
electrically-evoked secretory response during colitis.  
 
Interestingly, this mechanism of enteric glial dysfunction does not seem to persist following the 
resolution of intestinal inflammation. In TNBS treated mice, normal secretory function was 
restored following a three-week post-inflammation period, and was unaltered by fluoroacetate, 
suggesting that the process in which enteric glia dysregulate ion transport is pathological.  
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We used human biopsy samples in Ussing chambers to describe ion transport in the distal 
and/or rectosigmoid colon of patients with IBD, comparing inflamed and uninflamed regions 
from these patients. We found no difference in the ion transport response to EFS between the 
inflamed and uninflamed regions of the colon in the presence or absence of glial metabolic 
poison fluoroacetate. Responses to electrical field stimulation in these preparations are likely 
due to direct axonal activation and because the neurons of the ENS are mostly absent, these 
results are consistent with our findings in the mouse.  The lack of difference in EFS response in 
inflamed vs. uninflamed tissues suggests that glia-derived NO is acting on neuronal cell bodies 
in the ENS and not at the level of the epithelium.  At this point additional human tissue 
experiments in full-wall thickness preparations is required to confirm the results of our findings 
in mice.  
 
The functional consequences of our findings are important as we found that fluoroacetate 
treatment decreased or prevented bacterial translocation and reduced colitis, without any 
antibacterial effects on the growth of common strains of bacteria found in normal gut flora. 
Fluoroacetate restored chloride secretion in colitis, which is a known mechanism of host 
defense against bacteria and other pathogens crossing into the gut tissue from the lumen56. 
The absence of appropriate chloride secretion during intestinal inflammation may allow 
bacterial translocation, precipitating or exacerbating inflammation. The inhibition of enteric glia 
and their production of NO may reverse this effect and permit chloride secretion to occur, 
thereby preventing this harmful process.  
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In conclusion, we have demonstrated a novel role for enteric glia located in the ENS in the 
dysregulation of intestinal ion transport during colitis.  Enteric glial-derived factors, including 
NO, may have detrimental functional consequences on the integrity of the epithelial barrier, 
and, as a result, on the severity of colitis. Additionally, these findings provide a deeper 
understanding of the communication between neurons and enteric glia in the dysregulation of 
homeostasis during intestinal inflammation, and suggest that enteric glia could be a novel 
therapeutic target in the treatment of IBD. 
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FIGURE LEGENDS 
Figure 1. A. Recordings demonstrating short-circuit current (ISC) response to EFS and forskolin 
(FSK) in full-wall thickness colon (I.), ISC in the presence of TTX (II.) and in chloride-free buffer 
(III.) from control mice.  B. EFS responses in the presence of NOS1 (SMTC), NOS2 (1400W) and 
NOS1 and NOS2 inhibitors (n=6/group).  C. EFS responses in saline control and TNBS colitis in 
the presence and absence of NOS1 and NOS2 inhibitors (n=4/group). D. EFS responses in 
control and DSS colitis in the presence and absence of NOS1 and NOS2 inhibitors (n=4-
10/group). *P<.05; **P<.01; ***P<.001 compared to non-inflamed control; #P<.05; compared to 
inflamed control. 
Figure 2.  EFS responses in control (A., B.), TNBS colitis (A.) and DSS colitis (B.) in the presence 
and absence of fluoroacetate (FA) and FA in combination with the NOS2 inhibitor 1400W during 
TNBS colitis (n=6-10/group).  C. EFS responses in Il10-/- mice and their wildtype controls (SvEv, 
n=3) in the presence and absence of FA. *P<.05; **P<.01; ***P<.001 compared to non-inflamed 
control or as specified; #P<.05; ###P<.001 compared to inflamed control. 
Figure 3. A. ISC responses to EFS in the presence and absence of fluoroacetate (FA) in saline 
control and 3 weeks after TNBS treatment (n=5-9). B. ISC responses to EFS in the presence and 
absence of forskolin (FSK) in saline control and 3 weeks post TNBS treatment (n=4-7). 
Figure 4.  A. & B. ISC responses to forskolin (FSK) in the presence and absence of fluoroacetate 
(FA) in control (A., B.), TNBS colitis (A.) and DSS colitis (B.).  Note that the FSK response was 
greatly reduced by colitis and not altered by FA (n=6-18/group).  C. & D. ISC responses to VIP in 
the presence and absence of FA in TNBS colitis (C.) and DSS colitis (D.).   Note that the 
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responses to VIP are significantly greater in the presence of FA (n=5-9/group). E. & F.  ISC 
responses to VIP in the presence of TTX and FA + TTX in TNBS colitis (E.) and DSS colitis (F.).  
Note that TTX blocked the ability of FA to restore the VIP responses (n=3/group).  *P<.05; 
**P<.01; ***P<.001 compared to non-inflamed control; #P<0.05 compared to inflamed control. 
Figure 5.  A.  Recording of nitric oxide (NO) production from the myenteric plexus following 
veratridine stimulation in the presence and absence of fluoroacetate (FA) under control 
conditions. B. NO production from the myenteric plexus from control animals in response to 
veratridine in the presence and absence of NOS1 (SMTC), NOS2 (1400W) and NOS1 and NOS2 
inhibitors (n=5-6/group). C. & D. NO production from the myenteric plexus in response to 
veratridine from animals with TNBS colitis (C.) and DSS colitis (D.) in the presence and absence 
of NOS1 (SMTC), NOS2 (1400W) and NOS1 and NOS2 inhibitors (n=3-6/group). E. & F. NO 
production from the myenteric plexus in response to veratridine from animals with TNBS colitis 
(E.) and DSS colitis (F.) treated with FA in the presence and absence of NOS1 (SMTC), NOS2 
(1400W) and NOS1 and NOS2 inhibitors (n=3-6/group). ***P<.001 compared to veratridine; 
#P<.05; ###P<.001 compared to veratridine + 1400W. 
Figure 6.  DCA stimulated NO production from the mucosa in the presence of the NOS2 
inhibitor 1400W and fluoroacetate (FA).  Note that FA has no effect on DCA-induced NO 
production (n=4-10/group). ***P<.001. 
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